Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s stock price was up 4.4% during trading on Thursday . The stock traded as high as $1.92 and last traded at $1.92. Approximately 9,470 shares traded hands during trading, a decline of 69% from the average daily volume of 30,220 shares. The stock had previously closed at $1.84.
Humacyte Stock Performance
The firm’s 50-day simple moving average is $1.85 and its 200-day simple moving average is $1.84.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- Basic Materials Stocks Investing
- Battle of the Retailers: Who Comes Out on Top?
- What Is WallStreetBets and What Stocks Are They Targeting?
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
